Kh.S. KHAERTYNOV¹, Sh.R. GALEEV^2,3

¹Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

²Kazan State Medical Academy, 36 Butlerov Str., Kazan, Russian Federation, 420012

³Republican Clinical Hospital of the MH of RT, 138 Orenburgskiy Trakt, Kazan, Russian Federation, 420064

Khaertynov Kh.S. ― Cand. Med. Sc., Associate Professor of the Department of Children’s Infections, tel. +7-903-342-96-27, e-mail: khalit65@rambler.ru

Galeev Sh.R. ― Cand. Med. Sc., Associate Professor of the Department of Urology and Nephrology, doctor of the Department of Kidney Transplantation, tel. +7-917-237-16-50, e-mail: shamil016@gmail.com

The article reviews the modern literature on the problem of the influence of cytomegalovirus infection on patients after solid organs transplantation. The review discusses the issues of pathologies after solid organ transplantation, strategies to prevent cytomegalovirus infection after transplantation in patients receiving immunosuppressive therapy. It shows the effect of cytomegalovirus infection on the survival of patients and implants.

Key words: solid organs transplantation, cytomegalovirus, infection, prevention.

REFERENCES

1. Prokopenko E.I. Viral infections and kidney transplantation (Review of literature). Nefrologiya i dializ, 2003, 5 (2), pp. 6-13 (in Russ.).
2. Got’e S.V. Infektsii v transplantologii [Infection in Transplantation]. Moscow: Triada, 2010. 382 p.
3. Sinzger C., Digel M., Jahn G.Cytomegalovirus cell tropism. Current Topics in Microbiology and Immunology, 2008, 325, pp. 63-83.
4. Michael J. Cannon. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infectious Diseases, 2007, 7, p. 71.
5. Michael J. Cannon., Scott Schmid D., Terri B. Hyde Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev. Med. Virol, 2010, 20, pp. 202-213.
6. Manicklal S., Emery V.C., Lazzarotto T. et al. The “silent” global burden of congenital cytomegalovirus. Clinical Microbiology Reviews, 2013, 26 (1), pp. 86-102.
7. Dzieciatkowski T., Tomaszewska A., Przybylski M. et al. Analysis of the shedding of three β-herpesviruses DNA in Polish patients subjected to allogeneic hematopoietic stem cell transplantation: Six-year follow up. J. Clin. Virol, 2016, 76, pp. 30-35.
8. Vatazin A.V., Got’e S.V., Moysyuk Ya.G. et al. Tsitomegalovirusnaya infektsiya u vzroslykh posle transplantatsii solidnyk horganov. Klinicheskie rekomendatsii. Ministerstvozdravookhraneniya Rossiyskoy Federatsii [Cytomegalovirus infection in adults after solid organ transplantation. Clinical guidelines]. Moscow, 2014. 63 p.
9. Volkova S.D., Chebotkevich V.N., Kir’yanova G.Yu. et al. Algorithm ensure CMV-negative patients at risk gemokomponentami. Transfuziologiya, 2015, 1, pp. 35-37 (in Russ.).
10. Elfath M., Luka J., Tahhan R. et al. Detection of CMV by polymerase chain reaction (PCR) in seropositive blood donors. Transfusion, 1996, 36, p. 34.
11. Dodd R.Y., Notari E.P., Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 2002, 42, pp. 975-979.
12. Ramanan P., Razonable P.P. Cytomegalovirus Infections in Solid Organ Transplantation: A Review. Infect. Chemother, 2013, 45 (3), pp. 260-271.
13. Razonable R.R. Cytomegalovirus in Solid Organ Transplantation. American Journal of Transplantation, 2013, 13, pp. 93-106.
14. Sadovskiy D.N., Kalachik O.V., Yunis N. et al. Cytomegalovirus infection in kidney transplantation. Meditsinskiy zhurnal, 2012, no. 4, pp. 85-88 (in Russ.).
15. Snydman D.R., Falagas M.E., Avery R.et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: A multicenter, open-label study. Transplant Proc, 2001, 33, pp. 2571-2575.
16. Bonaros N., Mayer B., Schachner T. et al. CMV hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis. Clin. Transplant, 2008, 22, pp. 89-97.
17. Opelz G., Daniel V., Naujokat H. et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol, 2007, 8, pp. 212-218.
18. Khoury J.A., Storch G.A., Bohl D.L. et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am. J. Transplant, 2006, 6, pp. 2134-2143.
19. Kliem V., Fricke L., Wollbrink T., Burg M., Radermacher J., Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am. J. Transplant, 2008, 8, pp. 975-983.
20. Reischig T., Jindra P., Hes O., Svecova M., Klaboch J., Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am. J. Transplant, 2008, 8, pp. 69-77.
21. Witzke O., Hauser I.A., Bartels M. et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation, 2012, 93, pp. 61-68.
22. Mark D. Pescovitz Formulary Considerations for Drugs Used to Prevent Cytomegalovirus Disease. Disclosures Am. J. Health Syst. Pharm, 2003, 60, p. 23.
23. Khoury J.A., Storch G.A., Bohl D.L. et. al. Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients. American Journal of Transplantation, 2006, vol. 6, I. 9, pp. 2134-2143.